<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04728269</url>
  </required_header>
  <id_info>
    <org_study_id>DEABIOM</org_study_id>
    <nct_id>NCT04728269</nct_id>
  </id_info>
  <brief_title>Exploratory Study on Lactibiane Topic AD on Skin Flora and Barrier Reinforcement in Mild to Moderate Atopic Dermatitis</brief_title>
  <official_title>Exploratory Study to Assess the Impact of a Cosmetic Product (Lactibiane Topic AD) on Skin Flora and Skin Reinforcement Barrier in Mild to Moderate Atopic Dermatitis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>PiLeJe</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>PiLeJe</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This exploratory study aims to evaluate the impact of a cosmetic product (Lactibiane Topic&#xD;
      AD) vs placebo on skin flora and skin reinforcement barrier in mild to moderate atopic&#xD;
      dermatitis using biometrological, biological and clinical parameters.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">August 19, 2020</start_date>
  <completion_date type="Actual">December 9, 2020</completion_date>
  <primary_completion_date type="Actual">December 9, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in skin flora composition</measure>
    <time_frame>from baseline (Day 0) at Day 21</time_frame>
    <description>16S rRNA sequencing, qPCR</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in skin flora composition</measure>
    <time_frame>from baseline (Day 0) at Day 14</time_frame>
    <description>16S rRNA sequencing, qPCR</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Skin barrier status</measure>
    <time_frame>Day 0, Day 14, Day 21</time_frame>
    <description>TransEpidermal Water Loss (TEWL)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient Oriented SCORing Atopic Dermatitis</measure>
    <time_frame>Day 0, Day 14, Day 21</time_frame>
    <description>Patient Oriented SCORing Atopic Dermatitis (POSCORAD): 0 - 103 (Higher values represent a worse outcome)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>SCORing Atopic Dermatitis</measure>
    <time_frame>Day 0, Day 14, Day 21</time_frame>
    <description>SCORing Atopic Dermatitis (SCORAD) : 0 - 103 (Higher values represent a worse outcome)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical severity of lesional areas</measure>
    <time_frame>Day 0, Day 14, Day 21</time_frame>
    <description>Scoring of lesional area by subject and investigator : 0-18 (Higher values represent a worse outcome)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Manifestation of adverse local reactions</measure>
    <time_frame>From Day 0 to Day 21</time_frame>
    <description>Subjects will use a diary to document any potential adverse reactions observed after product application</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">10</enrollment>
  <condition>Atopic Dermatitis</condition>
  <arm_group>
    <arm_group_label>Lactibiane topic AD</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Cosmetical product Lactibiane Topic AD</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo made with the same base as the cosmetical product</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Lactibiane Topic AD</intervention_name>
    <description>Application of Lactibiane topic AD twice a day (morning and evening) on one lesional area</description>
    <arm_group_label>Lactibiane topic AD</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Application of placebo twice a day (morning and evening) on the symmetrical lesional area</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Subject diagnosed with mild to moderate AD defined as SCORAD≤40 (Eichenfield et al.&#xD;
             JAAD 2014).&#xD;
&#xD;
          -  Subject with at least two symmetric AD lesions with comparable severity: Located&#xD;
             either on upper extremities (left and right arms except hands) or lower extremities&#xD;
             (left and right legs except feet), With an erythema ≥ 1 (mild to severe intensity),&#xD;
             With a lesional area score ≥ 4 on both lesions with an authorized delta of two points&#xD;
             between the two lesions, With a sufficient extent to allow all the investigations.&#xD;
&#xD;
          -  Subject with I, II, III or IV skin phototype (according to Fitzpatrick's scale).&#xD;
&#xD;
          -  For woman of childbearing potential (defined as all women physiologically capable of&#xD;
             becoming pregnant): Negative urine pregnancy test at inclusion visit. Use of a highly&#xD;
             effective method of birth control* during the study. * A highly effective method of&#xD;
             birth control is defined as one which results in a low failure rate (less than 1%)&#xD;
             when used consistently and correctly, such as implants, combined oral contraceptives,&#xD;
             intrauterine device, double barrier methods (e.g. condom with spermicide), sexual&#xD;
             abstinence or vasectomized partner.&#xD;
&#xD;
          -  Subject with health insurance coverage according to local regulation.&#xD;
&#xD;
          -  Subject having given his written informed consent.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Subject having a known hypersensitivity, allergy or contraindication to any&#xD;
             ingredients contained within the investigational product or placebo.&#xD;
&#xD;
          -  Subject having exposed his skin to natural or artificial UV within 8 weeks prior to&#xD;
             the inclusion visit or intending to expose his skin during the study.&#xD;
&#xD;
          -  Subject having performed phototherapy within 8 weeks prior to the inclusion visit or&#xD;
             intending to perform phototherapy during the study.&#xD;
&#xD;
          -  Subject having performed another physical treatment (e.g radiotherapy…) on the&#xD;
             investigational areas within 6 months prior to the inclusion visit or intending to&#xD;
             perform it during the study.&#xD;
&#xD;
          -  Subject treated with systemic non-steroidal anti-inflammatory drugs (≥3 days) within 1&#xD;
             week before the inclusion visit.&#xD;
&#xD;
          -  Subject treated with biological immunosuppressive drugs within 12 weeks prior to the&#xD;
             inclusion visit or intending to be treated with it during the study.&#xD;
&#xD;
          -  Subject treated with non-biological immunosuppressive drugs within 4 weeks prior to&#xD;
             the inclusion visit or intending to be treated with it during the study.&#xD;
&#xD;
          -  Subject treated with systemic corticoids within 1 week prior to the inclusion visit or&#xD;
             planed during the study.&#xD;
&#xD;
          -  Subject treated with systemic antibiotics within 7 days prior to the inclusion visit&#xD;
             or planed during the study.&#xD;
&#xD;
          -  Subject having applied topical immunomodulators, non-steroidal anti-inflammatory,&#xD;
             corticoids or antihistamines on investigational limbs within 1 weeks prior to the&#xD;
             inclusion visit.&#xD;
&#xD;
          -  Subject having applied topical antibiotics or disinfectants on investigational limbs&#xD;
             within 2 weeks prior to the inclusion visit.&#xD;
&#xD;
          -  Subject having applied any other topical and/or care product after the last grooming&#xD;
             prior to the inclusion visit.&#xD;
&#xD;
          -  Subject having applied water or care product (except hands cleaning) within 12 hours&#xD;
             prior to the inclusion visit.&#xD;
&#xD;
          -  Subject having started, modified or stopped any other treatment/product within 4 weeks&#xD;
             prior to the inclusion visit or intending to do so during the study that according to&#xD;
             the investigator's judgment, could interfere with study results.&#xD;
&#xD;
          -  Subject having significant medical condition that according to the investigator's&#xD;
             judgment, deems inappropriate for study participation (e.g present or past malignancy,&#xD;
             present or past skin condition…).&#xD;
&#xD;
          -  Subject having significant dermatological condition or sign (e.g disease, scare,&#xD;
             abundant hairiness, tanning mark…) that according to the investigator's judgment,&#xD;
             could limit the observations or/and interfere with the interpretations.&#xD;
&#xD;
          -  Subject taking part or having participated in another clinical study within 2 weeks&#xD;
             prior to the inclusion visit.&#xD;
&#xD;
          -  Subject under legal guardianship or incapacitation.&#xD;
&#xD;
          -  Subject linguistically or psychologically unable of signing informed consent form and&#xD;
             unable to comply with the protocol requirements according to the investigator's&#xD;
             judgment.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Unité de Recherche Clinique en Immunologie - Lyon Sud</name>
      <address>
        <city>Pierre-Bénite</city>
        <zip>69495</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>January 2021</verification_date>
  <study_first_submitted>January 14, 2021</study_first_submitted>
  <study_first_submitted_qc>January 23, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">January 28, 2021</study_first_posted>
  <last_update_submitted>January 28, 2021</last_update_submitted>
  <last_update_submitted_qc>January 28, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">February 2, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dermatitis, Atopic</mesh_term>
    <mesh_term>Dermatitis</mesh_term>
    <mesh_term>Eczema</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

